Episode

If you’re not too early, you’re too late | Shelby Newsad, Partner at Compound VC

Podcast
Nucleate Podcast
Published
Apr 10, 2025
Duration seconds
2940
Processing state
not_requested
Canonical source
https://nucleate-signal.simplecast.com/episodes/if-youre-not-too-early-youre-too-late-shelby-newsad-partner-at-compound-vc-rdk_ywwI
Audio
https://cdn.simplecast.com/audio/6a0defb6-ad56-4c08-b015-fea36f1c159f/episodes/e15375bd-169a-461a-b0ca-bb0e0323df00/audio/6fa13c5c-aa6c-44fe-95ec-36ad857aa110/default_tc.mp3?aid=rss_feed&feed=OdcQl6Pu
JSON
/v1/public/podcasts/nucleate-podcast-6322042/episodes/if-you-re-not-too-early-you-re-too-late-shelby-newsad-partner-at-compound-vc
Markdown
/podcast/nucleate-podcast-6322042/if-you-re-not-too-early-you-re-too-late-shelby-newsad-partner-at-compound-vc.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/nucleate-podcast-6322042/episodes/if-you-re-not-too-early-you-re-too-late-shelby-newsad-partner-at-compound-vc/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/nucleate-podcast-6322042/if-you-re-not-too-early-you-re-too-late-shelby-newsad-partner-at-compound-vc.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode of the Nucleate Podcast, Shelby Newsad, Partner at Compound VC, shares her journey from a small town in Appalachia to investing in some of the most transformative technologies shaping biotech and beyond. Starting as a first-generation college student with a pre-med background, she realized that commercialization is key to translating scientific research into real-world impact. Shelby discusses her work at Compound, a thesis-driven, research-centric venture firm investing across AI, robotics, crypto, and biotech. She explains how Compound builds deep expertise in emerging fields — developing theses, connecting with researchers, and creating ecosystems around transformational areas — to become the highest-context investors for early-stage companies. When critical gaps in the market appear, Compound even incubates companies themselves, such as in plant engineering for high-value, lower-regulation products. The conversation dives into emerging trends like autonomous science, science-driven consumer products, biohacking, and proactive healthcare. Shelby highlights the importance of individual health data ownership, the potential for brain modulation technologies, and why bold, contrarian founders are key to the future of biotech. She shares her optimism for the future, from conservation tech to cancer prevention, and invites listeners to think bigger, move earlier, and reach out with innovative ideas — and to get involved with Compound’s upcoming Research Days in San Francisco.